Kimberly D. Thompson
University of Utah
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Kimberly D. Thompson.
Inflammatory Bowel Diseases | 2011
Jill C. Moore; Kimberly D. Thompson; Bonnie LaFleur; Linda S. Book; W. Daniel Jackson; Molly O'Gorman; Richard E. Black; Earl C. Downey; Dale G. Johnson; Michael E. Matlak; Rebecka L. Meyers; Eric R. Scaife; Stephen L. Guthery
Background: Clinical variables may identify a subset of patients with pediatric‐onset ulcerative colitis (UC) (≤18 years at diagnosis) at risk for adverse outcomes. We postulated that routinely measured clinical variables measured at diagnosis would predict colectomy in patients with pediatric‐onset UC. Methods: We conducted a chart review of patients with pediatric‐onset UC at a single center over a 10‐year period. We compared patients with and without colectomy across several variables, used proportional hazards regression to adjust for potential confounders, and assessed the ability of a UC risk score to predict colectomy. Results: Among 470 patients with inflammatory bowel disease ICD9‐coded encounters, 155 patients had UC and 135 were eligible for analysis. The 1‐ and 3‐year colectomy rates were 16.7% (95% confidence interval [CI]: 11.0%–24.8%) and 35.6% (26.7%–45.4%). White blood cell (WBC) count and hematocrit measured at diagnosis were associated with colectomy at 3 years, even after correcting for potential confounding variables. A UC Risk Score derived from the WBC count and hematocrit was strongly associated with colectomy risk, with a high negative predictive value (NPV) for colectomy at 1 and 3 years (NPV = 0.95 and 0.89, respectively), but low positive predictive value (PPV = 0.22 and 0.38, respectively). Conclusions: A risk score calculated from WBC and hematocrit measured at diagnosis was associated with, but incompletely predictive of, colectomy in pediatric‐onset UC. These data suggest 1) routinely measured clinical variables may have a prognostic role in risk stratification, and 2) multicenter prospective studies are needed to optimize risk stratification in pediatric UC. Our findings have impact on the design of such studies. (Inflamm Bowel Dis 2011;)
Inflammatory Bowel Diseases | 2016
Kimberly D. Thompson; Susan J. Connor; Danielle Walls; Jan Gollins; Sabrina K. Stewart; Meena Bewtra; Geri L. Baumblatt; Stefan D. Holubar; Astrid-Jane Greenup; Alexandra Sechi; Afaf Girgis; David T. Rubin; Corey A. Siegel
Background:Patients with ulcerative colitis (UC) are often fearful about medication side effects and how the disease will affect their future. Our aim was to better understand what aspects of UC, and UC management, are most concerning to patients, and how they would like to be informed about treatment options. Methods:A Web-based survey was sent to UC patients throughout the United States and Australia. In addition to standard closed-response questions, audio clips were embedded in the survey and respondents showed their strength of agreement or disagreement using moment-to-moment affect-trace methodology. Standard quantitative analysis was used for the survey results, and cluster analysis was performed on the affect-trace responses. Results:A total of 460 patients with UC (370 patients from the United States and 90 patients from Australia) responded to the survey. Of them, 53% of the respondents were women, with a mean age of 49 (range 19–81) years. Most patients (87%) wanted to share treatment decision making with their doctors. The majority, 98%, wanted more than just a basic understanding of their disease. Patients were most concerned about the risk of colorectal cancer (37%), and the possible need for an ileostomy (29%). Only 14% of patients indicated that side effects from medications were their biggest concern. On affect-trace analysis, the most divergence in opinion centered on the appropriate timing for colectomy. Conclusions:To facilitate informed treatment decisions for UC patients, in addition to reviewing the benefits and risks of medications, it is also important to discuss the best strategies for decreasing the risk of colectomy and colorectal cancer.
Gastroenterology | 2014
Corey A. Siegel; Henry A. Horton; Lori S. Siegel; Kimberly D. Thompson; Todd A. MacKenzie; Sabrina K. Stewart; Philip Rice; Joanne M. Stempak; Seper Dezfoli; Alexander Levy; Michael D. Baek; Raquel Milgrom; Parambir S. Dulai; Mark S. Silverberg; Marla Dubinsky; Dermot P. McGovern
Inflammatory Bowel Diseases | 2017
Shawn X. Li; Kimberly D. Thompson; Tracey Peterson; Shelley Huneven; Jamie Carmichael; Fredric J. Glazer; Katelyn Darling; Corey A. Siegel
Gastroenterology | 2017
Parambir S. Dulai; Jay C. Buckey; Laura H. Raffals; Jason M. Swoger; Paul L. Claus; Kevin S. O'Toole; Judy Ptak; Michael W. Gleeson; Christella E. Widjaja; Jeffrey M. Adler; Nihal Patel; Laurie A. Skinner; Shawn P. Haren; Kimberly Goldby-Reffner; Kimberly D. Thompson; Rob Knight; John T. Chang; Corey A. Siegel
Gastroenterology | 2017
Corey A. Siegel; Kimberly D. Thompson; Danielle Walls; Jan Gollins; Jean-Frederic Colombel; Edouard Louis
Gastroenterology | 2016
Shawn X. Li; Kimberly D. Thompson; Tracey Peterson; Shelley Huneven; Jamie Carmichael; Fredric J. Glazer; Katelyn Darling; Corey A. Siegel
Gastroenterology | 2015
Jennifer DiMuro; Kimberly D. Thompson; Damara Crate; Corey A. Siegel
Gastroenterology | 2018
Corey A. Siegel; Kimberly D. Thompson; Lori S. Siegel; Todd A. MacKenzie; Marla Dubinsky
Gastroenterology | 2018
Corey A. Siegel; Kimberly D. Thompson; Danielle Walls; Jan Gollins; Anne Buisson; Alain Olympie; Jean-Frederic Colombel; Edouard Louis